Granahan Investment Management’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-67,888
| Closed | -$11.7M | – | 205 |
|
|
2021
Q3 | $11.7M | Sell |
67,888
-12,420
| -15% | -$1.62M | 0.22% | 103 |
|
|
2021
Q2 | $10.1M | Buy |
80,308
+3,884
| +5% | +$490K | 0.19% | 114 |
|
|
2021
Q1 | $10.4M | Buy |
76,424
+17,950
| +31% | +$2.32M | 0.22% | 90 |
|
|
2020
Q4 | $7.48M | Sell |
58,474
-58,022
| -50% | -$6.8M | 0.17% | 108 |
|
|
2020
Q3 | $13.1M | Sell |
116,496
-17,395
| -13% | -$1.73M | 0.44% | 68 |
|
|
2020
Q2 | $12.8M | Sell |
133,891
-12,830
| -9% | -$1.24M | 0.46% | 64 |
|
|
2020
Q1 | $13.2M | Sell |
146,721
-64,611
| -31% | -$5.02M | 0.71% | 42 |
|
|
2019
Q4 | $11.2M | Sell |
211,332
-3,695
| -2% | -$168K | 0.52% | 57 |
|
|
2019
Q3 | $8.5M | Buy |
215,027
+10,583
| +5% | +$459K | 0.47% | 65 |
|
|
2019
Q2 | $8.4M | Sell |
204,444
-14,020
| -6% | -$580K | 0.42% | 69 |
|
|
2019
Q1 | $10.2M | Sell |
218,464
-14,738
| -6% | -$647K | 0.55% | 53 |
|
|
2018
Q4 | $10.2M | Sell |
233,202
-5,177
| -2% | -$259K | 0.72% | 47 |
|
|
2018
Q3 | $13.6M | Buy |
238,379
+10,895
| +5% | +$535K | 0.74% | 47 |
|
|
2018
Q2 | $11M | Sell |
227,484
-5,262
| -2% | -$192K | 0.67% | 48 |
|
|
2018
Q1 | $9.1M | Buy |
232,746
+6,515
| +3% | +$277K | 0.66% | 50 |
|
|
2017
Q4 | $9.6M | Buy |
226,231
+9,140
| +4% | +$343K | 0.76% | 42 |
|
|
2017
Q3 | $8.1M | Buy |
217,091
+28,694
| +15% | +$996K | 0.68% | 48 |
|
|
2017
Q2 | $5.72M | Buy |
188,397
+1,305
| +0.7% | +$37.8K | 0.53% | 69 |
|
|
2017
Q1 | $4.95M | Sell |
187,092
-493,117
| -72% | -$13M | 0.5% | 72 |
|
|
2016
Q4 | $17.4M | Sell |
680,209
-136,940
| -17% | -$4.34M | 0.6% | 68 |
|
|
2016
Q3 | $29.6M | Buy |
817,149
+57,530
| +8% | +$1.91M | 0.97% | 22 |
|
|
2016
Q2 | $25.8M | Buy |
759,619
+37,150
| +5% | +$1.21M | 0.94% | 30 |
|
|
2016
Q1 | $19.1M | Buy |
722,469
+66,078
| +10% | +$1.92M | 0.69% | 49 |
|
|
2015
Q4 | $32M | Buy |
656,391
+165,955
| +34% | +$5.97M | 1.1% | 20 |
|
|
2015
Q3 | $12.2M | Buy |
490,436
+21,400
| +5% | +$643K | 0.38% | 97 |
|
|
2015
Q2 | $14.8M | Sell |
469,036
-740
| -0.2% | -$23.9K | 0.42% | 86 |
|
|
2015
Q1 | $17.9M | Buy |
469,776
+163,788
| +54% | +$6.51M | 0.51% | 71 |
|
|
2014
Q4 | $11.9M | Buy |
+305,988
| New | +$10.7M | 0.35% | 105 |
|
Granahan Investment Management's XLRN Position: Q4 2021 in Review
Granahan Investment Management sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 67,888 shares — an estimated $11.7M sold.
Granahan Investment Management first reported a position in XLRN in Q4 2014 and held it in 28 quarters. The position peaked at $32M in Q4 2015. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Granahan Investment Management reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Granahan Investment Management sold 67,888 Acceleron Pharma shares in Q4 2021, an estimated $11.7M.
- Granahan Investment Management first reported a position in Acceleron Pharma in Q4 2014 and held it in 28 quarters.
- Granahan Investment Management's Acceleron Pharma position peaked at $32M in Q4 2015.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Granahan Investment Management's 13F filing for Q4 2021, filed 14 Feb 2022.